ATLANTA, July 19, 2010 (GLOBE NEWSWIRE) -- OTC Stock Review announces that it has initiated coverage of BioCurex, Inc. (OTCBB:BOCX). BioCurex is a developer of a blood-based diagnostic test for cancer that detects the presence of RECAF, a universal marker for malignant cell growth in humans and animals. BioCurex owns the proprietary technology related to the RECAF marker royalty-free, with patents granted in the United States, Europe and China. Patents are also pending in other major worldwide markets.
In its quest to become cash flow positive, BioCurex has recently created a wholly-owned subsidiary, OncoPet Diagnostics. OncoPet Diagnostics has launched its OncoPet RECAF test, which detects 85 percent of a variety of cancers in dogs, at the standard 95 percent specificity level, in pre-market studies. We believe this launch represents the first commercialization of a test of this type for the universal detection of cancer in companion animals. The OncoPet RECAF test for companion animals is not a substitution for the RECAF tests designed to detect cancer in human patients, but rather an addition aimed to accelerate revenue generation while the human tests move through the pre-marketing phases before commercialization. In our opinion, this represents a major step towards making BioCurex, Inc. a commercially successful enterprise, since the OncoPet RECAF tests, along with other initiatives will allow them to become cash flow positive within 18 months.
The complete report is available at http://www.otcstockreview.com/Files/BOCX/BOCX_Review.pdf.
More information on BioCurex and OncoPet Diagnostics is available at http://www.biocurex.com and http://www.oncopetdiagnostics.com.
NOTE: The purpose of this release is to introduce the reader to OTCStockReview.com and BioCurex. OTC Stock Review is not a Registered Investment Advisor or a Broker/Dealer. Information and opinions presented in this release are solely for informative purposes and not intended, nor should they be construed as, investment advice. This document contains information obtained from public sources about BioCurex, but does not contain all the relevant material information necessary to evaluate the company. This release is not to be considered an offer to buy, sell, hold, and/or otherwise trade in the securities of BioCurex, as profiled. OTC Stock Review has been compensated nine thousand dollars to perform investor relations services for BioCurex and officers, directors, and employees of OTC Stock Review, may hold a long or short equity position of a profiled company and may trade in these securities for their own accounts. Carefully review profiled companies with your investment advisor, stockbroker, or other such professional. OTC Stock Review is not liable for any investment decisions by its readers or their advisors. Readers are encouraged to obtain copies of the profiled Company's periodic reports filed with United States Securities and Exchange Commission, which are generally available at http://www.sec.gov. You can view our complete disclaimer at http://www.otcstockreview.com/disclaimer.htm